Free Trial

Chill Brands Group (CHLL) Competitors

Chill Brands Group logo
GBX 1.52 +0.12 (+8.43%)
As of 05:52 AM Eastern

CHLL vs. PXS, MXC, RGT, CEL, N4P, HELD, HLN, BXP, HIK, and HCM

Should you be buying Chill Brands Group stock or one of its competitors? The main competitors of Chill Brands Group include Provexis (PXS), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), N4 Pharma (N4P), Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), and HUTCHMED (HCM). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Chill Brands Group vs. Its Competitors

Provexis (LON:PXS) and Chill Brands Group (LON:CHLL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Provexis has higher revenue and earnings than Chill Brands Group. Chill Brands Group is trading at a lower price-to-earnings ratio than Provexis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Provexis£846.98K20.43-£619.15K-£0.03-27.96
Chill Brands Group£624.19K12.31-£3.64M-£0.01-151.80

Provexis has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Chill Brands Group has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

7.9% of Provexis shares are held by institutional investors. Comparatively, 0.2% of Chill Brands Group shares are held by institutional investors. 21.6% of Provexis shares are held by insiders. Comparatively, 24.2% of Chill Brands Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Chill Brands Group had 2 more articles in the media than Provexis. MarketBeat recorded 2 mentions for Chill Brands Group and 0 mentions for Provexis. Chill Brands Group's average media sentiment score of 0.34 beat Provexis' score of 0.00 indicating that Chill Brands Group is being referred to more favorably in the news media.

Company Overall Sentiment
Provexis Neutral
Chill Brands Group Neutral

Chill Brands Group has a net margin of 0.00% compared to Provexis' net margin of -73.10%. Provexis' return on equity of -68.68% beat Chill Brands Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Provexis-73.10% -68.68% -56.14%
Chill Brands Group N/A -2,802.21%-44.64%

Summary

Provexis beats Chill Brands Group on 7 of the 13 factors compared between the two stocks.

Get Chill Brands Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHLL and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHLL vs. The Competition

MetricChill Brands GroupDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£7.69M£2.23B£5.61B£3.10B
Dividend YieldN/A2.92%4.61%5.04%
P/E Ratio-151.804.1330.29169.18
Price / Sales12.31686.16470.61307,479.17
Price / Cash11.5010.3738.2127.94
Price / BookN/A11.138.865.26
Net Income-£3.64M£20.70B£3.25B£5.89B
7 Day PerformanceN/A3.49%3.72%-0.01%
1 Month PerformanceN/A6.29%5.86%0.74%
1 Year PerformanceN/A3.23%30.49%62.68%

Chill Brands Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHLL
Chill Brands Group
N/AGBX 1.52
+8.4%
N/AN/A£7.69M£624.19K-151.807Gap Down
PXS
Provexis
N/AGBX 0.70
-5.8%
N/A+29.1%£16.31M£846.98K-26.354Gap Down
MXC
Argent BioPharma
N/AN/AN/AN/A£9.65M£1.32M-13.255Gap Up
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/A-0.65N/AGap Down
High Trading Volume
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat
N/AN/A£8.22M£123.38K-1.682,780
N4P
N4 Pharma
N/AGBX 0.50
+11.1%
N/A-10.7%£2.15M£8.84K-1.445Gap Up
HELD
Hellenic Dynamics
N/AGBX 0.01
flat
N/AN/A£14KN/A0.00N/A
HLN
Haleon
1.3734 of 5 stars
GBX 350.80
+0.8%
GBX 413.50
+17.9%
-4.3%£31.66B£11.07B29.5025,408High Trading Volume
BXP
Beximco Pharmaceuticals
N/AGBX 45
+3.4%
N/A+40.7%£30.68B£7.08T4.835,500Gap Up
HIK
Hikma Pharmaceuticals
4.0315 of 5 stars
GBX 1,746
-7.3%
GBX 2,560
+46.6%
-14.2%£4.84B£3.74B17.139,100Analyst Forecast
Gap Down
High Trading Volume
HCM
HUTCHMED
N/AGBX 268
+2.7%
N/A-20.0%£2.91B£771.01M-68.401,760Gap Up

Related Companies and Tools


This page (LON:CHLL) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners